Maternal hyperoxygenation: A potential therapy for congenital heart disease in the fetuses? A systematic review of the current literature.
Jennifer G Co-VuDalia Lopez-ColonHimesh V VyasNatalie WeinerCurt DeGroffPublished in: Echocardiography (Mount Kisco, N.Y.) (2018)
The current evidence for MH therapy suggests an increase in pulmonary blood flow, and venous return, ductal flow, and heart dimensions in fetuses. MH has potential as a diagnostic and therapeutic tool in fetuses with CHD. Further randomized controlled trials are needed to ascertain whether MH therapy provides improved outcomes on fetuses with certain types of CHD.
Keyphrases
- gestational age
- congenital heart disease
- blood flow
- birth weight
- randomized controlled trial
- systematic review
- preterm birth
- heart failure
- pulmonary hypertension
- human health
- type diabetes
- risk assessment
- atrial fibrillation
- adipose tissue
- stem cells
- physical activity
- cell therapy
- weight loss
- bone marrow
- glycemic control